- Clone:
- REA431 | 50C1
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for CD371 (CLEC12A) Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD371 (CLEC12A) (REA431) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
Fluorescence microscopy image of CD371 (CLEC12A) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD371 (CLEC12A)-PE (REA431, red) and counterstained with DRAQ5 (blue) as DNA stain.
Overlay histogram showing flow cytometric analysis of CD371 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD371-PE, clone (REA431). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD371 (CLEC12A). Human peripheral blood mononuclear cells (PBMCs) were stained with CD371 (CLEC12A) antibodies and with a suitable counterstaining. As a control, CD371 (CLEC12A) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD371 (CLEC12A) shown as histograms
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD371 (CLEC12A) (REA431). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA431 recognizes CD371, the human C-type lectin domain family 12 member A (CLEC12A) antigen, a single-pass type II membrane protein which is also known as C-type lectin-like molecule 1 (CLL-1), dendritic cell-associated lectin 2 (DCAL2), or myeloid inhibitory C-type lectin-like receptor (MICL). CD371 (CLEC12A) is a immunoreceptor tyrosine-based inhibitory motif (ITIM) containing C-type lectin receptor encoded within the dectin-1 cluster. This receptor binds unknown endogenous ligands and is widely expressed on innate immune cells, including neutrophils, monocytes, macrophages, and dendritic cells (DCs). There are conflicting data on its expression on human natural killer (NK) cells. Its intracellular ITIM sequence recruits the tyrosine phosphatases SHP-1 and SHP-2 to negatively regulate Syk signaling. Because the expression of CD371 (CLEC12A) can be downregulated under inflammatory conditions, this receptor might be involved in the control of myeloid cell activation. CD371 (CLEC12A) has been shown to enhance LPS responses and to induce expression of CCR7, a chemokine involved in DC migration. It has been proposed that signals from CD371 (CLEC12A) may synergize with signals from other receptors to facilitate DC responses such as migration and T cell stimulation.
Additional information: Clone REA431 displays negligible binding to Fc receptors.
MICL, CLL-1, DCAL-2
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Lahoud, M. H. et al. (2009) The C-type lectin Clec12A present on mouse and human dendritic cells can J Immunol 182 (12): 7587-7594
- Bakker, A. B. et al. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 64 (22): 8443-8450
- Neumann, K. et al. (2014) Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity 40 (3): 389-399